Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801027 | 0.89 | MAPT (0.59) | ALDH1A1TDP1MEN1PSMD14PRKACA | |
| Ether SCHEMBL11452567 | 0.88 | ALDH1A1 (0.49) | ALDH1A1TDP1CRHBPCRHR2ALOX5 | |
| SCHEMBL13603461 | 0.86 | MEN1 (0.64) | ALDH1A1TDP1CRHBPCRHR2ALOX5 | |
| SCHEMBL29950169 | 0.85 | ESR1 (0.57) | ALDH1A1MAPTESR2ESR1AR | |
| SCHEMBL6796101 | 0.85 | ESR1 (0.57) | ALDH1A1MAPTESR2ESR1AR | |
| SCHEMBL10554893 | 0.82 | CYP11B1 (0.50) | MAPTESR2ESR1RAB9ANPC1 | |
| SCHEMBL3276362 | 0.81 | TDP1 (0.66) | ALDH1A1TDP1CRHBPCRHR2MEN1 | |
| SCHEMBL30352851 | 0.81 | TDP1 (0.66) | ALDH1A1TDP1CRHBPCRHR2MEN1 | |
| SCHEMBL15461976 | 0.81 | ALDH1A1 (0.69) | ALDH1A1TDP1CRHBPCRHR2MEN1 | |
| SCHEMBL2137404 | 0.80 | ALDH1A1 (0.63) | ALDH1A1TDP1CRHBPCRHR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116529252-A | Prodrugs for sustained release of therapeutic agents and uses thereof | 重庆两江药物研发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-2934594-B1 | CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . | ALMIRALL SA (ES) | 2019-09-04 | — | — | EP | disclosed |
| CN-105142673-B | Novel cyclohexyl and quininuclidinyl carbamate derivatives with beta 2-adrenergic activator and M3 muscarinic antagonists activity | 阿尔米雷尔有限公司 | 2018-01-05 | — | — | CN | disclosed |
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| CN-105142673-A | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL SA | 2015-12-09 | — | — | CN | disclosed |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2015-11-19 | — | — | US | disclosed |
| EP-2934594-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | Almirall, S.A. (ES) | 2015-10-28 | — | — | EP | disclosed |
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| CN-102459231-B | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2015-04-22 | — | — | CN | disclosed |
| WO-2014095920-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2014-06-26 | — | — | WO | disclosed |
| CN-102459231-A | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-6610893-B2 | Selectively nitrating 4-hydroxybiphenyl in the position adjacent to the phenolic hydroxyl group | BAYER AKTIENGESELLSCHAFT (DE) | 2003-08-26 | — | — | US | disclosed |
| US-20030055294-A1 | Method for producing 4-hydroxy-3-nitrobiphenyl | LANXESS DEUTSCHLAND GMBH (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2001032605-A1 | PROCESS FOR THE PREPARATION OF INSECTICIDAL PHENYLHYDRAZINE DERIVATIVES | CROMPTON CORPORATION (US) | 2001-05-10 | — | — | WO | disclosed |
| CN-1082023-A | The medicine and the novel benzoic acid derivative that contain benzoic acid derivative | YAMANOUCHI PHARMA CO LTD (JP) | 1994-02-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | ALDH1A1 1896/4885TDP1 4429/4885CRHBP 2908/4885 |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | CHRM3, CHRM2, ADRB2 | ALDH1A1 2719/4885TDP1 4563/4885CRHBP 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.